Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05495139
Other study ID # HZTJ03
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date November 30, 2023

Study information

Verified date August 2022
Source Hangzhou Tangji Medical Technology Co., Ltd.
Contact Ziru Liu
Phone 0571-86702039
Email lzr@tangjimedical.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.


Description:

The Gastric Bypass Stent System is intended to be used in Patients with Diagnosis of nonalcoholic fatty liver disease, Proton density fat fraction measured by magnetic resonance imaging (MRI-PDFF) ≥8%. In this pivotal, prospective, single-arm clinical investigation the Sponsor seeks to demonstrate the safety and performance of the Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date November 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: ( - ) Males or females with age between 18 and 65 years old; ( - ) Diagnosis of nonalcoholic fatty liver disease; ( - ) Proton density fat fraction measured by magnetic resonance imaging (MRI-PDFF) =8%; ( - ) BMI=24; Patients who understand the objective of the study; voluntarily participate in the study and have signed the informed consent form; and are able and willing to comply with all requirements, including follow up and evaluations. Exclusion Criteria: ( - ) History of excessive alcohol consumption (alcohol consumption equivalent to ethanol > 30 g/d for males and > 20 g/d for females); ( - ) End-stage liver disease (e.g. hepatic cirrhosis or hepatic cancer) or other conditions which may lead to fatty liver; ( - ) Unable to cooperate to complete MR examination; ( - ) Subjects who have used any nonsteroidal anti-inflammatory drug or corticosteroid in the past month; ( - ) Patients with iron deficiency or iron deficiency anemia; ( - ) ALT or AST increased to 8 × upper limit of normal (ULN), and bilirubin increased to 2×ULN; ( - ) Patients with coagulation disorder or haemorrhagic diathesis (platelets <100×109/L); ( - ) Patients with duodenal ulcer, or previous or existing pancreatitis; ( - ) History of liver abscess; ( - ) History of gallstones (symptomatic or presenting of any stone with a diameter greater than 20mm); ( - ) Patients with gastrointestinal hemorrhage or potential hemorrhage; ( - ) Gastrointestinal tract anomalies, such as gastrointestinal tract atresia or any or other conditions that would result in failed placement in the gastrointestinal tract; ( - ) Patients with history of intestinal obstruction or related disease in the past year; ( - ) Drug abusers or patients with uncontrollable psychiatric disorders; ( - ) Patients with any contraindication to endoscopy based on the investigator's judgment; ( - ) Pregnancy or lactating women; ( - ) Patients who are participating in any other drug or medical device clinical study; ( - ) Patients with any other conditions evaluated by the investigators as unsuitable for participating in the trial;

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hangzhou Tangji Medical Technology Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of MRI-PDFF Changes of MRI-PDFF at device retrieval 24 weeks after device implantation procedure(Visit 7)
Secondary Changes of MRI-PDFF Changes of MRI-PDFF at 12 and 24 weeks after device retrieval 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Changes of liver stiffness measurement (LSM) Changes of liver stiffness measurement (LSM) at device retrieval, and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Changes of liver inflammation/injury indicators (ATL, ASL, GGT, ALP, TBil, and DBil) Changes of liver inflammation/injury indicators (ATL, ASL, GGT, ALP, TBil, and DBil) at device retrieval, and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Changes of blood glucose indicators (fasting insulin, fasting blood glucose, fasting C-peptide, and insulin resistance [e.g. HOMA-IR]) Changes of blood glucose indicators (fasting insulin, fasting blood glucose, fasting C-peptide, and insulin resistance [e.g. HOMA-IR]) at device retrieval, and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Changes of blood lipids indicators, including triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, and lipoprotein (a) Changes of blood lipids indicators, including triglyceride, total cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, and lipoprotein (a), at device retrieval, and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Changes of hepatic fibrosis indicators (PIIINP, Fibro Test/Fibro Sure, ELF, and NFS) Changes of hepatic fibrosis indicators (PIIINP, Fibro Test/Fibro Sure, ELF, and NFS) at device retrieval, and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Percent changes of body weight and changes of BMI Percent changes of body weight and changes of BMI at device retrieval and 12 and 24 weeks after device retrieval 24 weeks after the implantation procedure (Visit 7), and 12 weeks after device retrieval(Visit 8) and 24 weeks after device retrieval(Visit 9)
Secondary Histological changes Histological changes at device retrieval 24 weeks after the implantation procedure (Visit 7)
Secondary Evaluation on the usability of the device Use abdominal X-ray evaluate Device implantation status 4 weeks after the implantation procedure (Visit 4) ?12 weeks after the implantation procedure (Visit 5)and 18 weeks after the implantation procedure (Visit 6)
See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT01045499 - LAGB as a Treatment for Morbid Obesity in Adolescents N/A
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Completed NCT04988204 - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04369521 - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Enrolling by invitation NCT00983463 - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting NCT00658164 - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Phase 3
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT06441409 - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT01735799 - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS N/A
Completed NCT01446276 - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease N/A
Completed NCT00930384 - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis N/A
Recruiting NCT02469272 - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Phase 1
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Completed NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Phase 2
Terminated NCT01355575 - Rifaximin in Fatty Liver Disease Phase 4
Completed NCT01210989 - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis N/A
Completed NCT03434613 - Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Phase 4